Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2005

View Archived Issues

Topotecan may be useful as an alternative to etoposide in retinoblastoma treatment

p53 inhibitor demonstrates neuroprotection in vivo

Targeting p38 MAP kinase attenuates LA-mediated neurotoxicity and nerve injury evoked pain

Spotlight on sodium channel Nav1.8 in pain

GSK-3beta inhibitors tested in a model of sepsis-associated muscle wasting

New data on the antifungal efficacy of posaconazole in HSCT recipients with GVHD

Phase III data support the use of regadenoson in MPI studies

Gantacurium induces mild histamine release in healthy volunteers

Aradigm and United Therapeutics sign agreement for inhaleable PAH treatment

Hana Biosciences completes private placement

GlycoGenesys announces USD 20 million common stock purchase agreement

SNT-MC17 begins phase IIa study for Duchenne muscular dystrophy

Oxymetazoline shortens the duration of colds in study

Enrollment completed in phase I/II eczema study of Avrina

FDA Advisory Committee votes on Emsam

Topigen licenses rights to NicOx's NCX-1020 for COPD

U.K. phase II trial of Hemopure cleared to begin

Pivotal phase III study for ZymoGenetics' rhThrombin

Sankyo discontinue pactimibe studies

Kyorin executes license with LG Life Sciences for KRP-197

Toyama Chemical and Taiho collaborate on development of YP-18

Amygdalin peptidomimetics present improved profile as potential antipsoriatic agents

Update on memantine in Alzheimer's disease and alcohol withdrawal

New treatments for cancer covered in recent patents

New therapeutic agents for respiratory disorders revealed in patent literature

Aricept sNDA not accepted for filing due to formatting deficiencies

Kepivance receives European approval

Antiarthritic agents prepared and tested

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...